Annotation Detail
Information
- Associated Genes
- DNMT3A
- Associated Variants
-
DNMT3A MUTATION
DNMT3A MUTATION - Associated Disease
- acute myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- Among 46 AML patients treated with decitabine, the response rate was 75% (6/8) among DNMT3A mutated and 34% (13/38) among DNMT3A wild-type patients (P=.008)
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1587
- Gene URL
- https://civic.genome.wustl.edu/links/genes/18
- Variant URL
- https://civic.genome.wustl.edu/links/variants/189
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Acute Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Decitabine
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22124213
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Decitabine | Sensitivity | true |